We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New, Enzyme-Free Glucose Monitoring Sensor Solution Could Find Applications in Range of POC Diagnostics

By LabMedica International staff writers
Posted on 03 Feb 2022

Researchers have developed a new glucose sensor that is cheaper and more robust than current systems, opening up the possibility of taking the underlying applied methodology to a vast range of similar point-of-care diagnostics. More...

Researchers at the University of Bath (Bath, UK) working in collaboration with industrial partner, Integrated Graphene (Stirling, UK) have developed a new sensing technique based on graphene foam for the detection of glucose levels in the blood. Since it is a chemical sensor instead of being enzyme-based, the new technology is robust, has a long shelf-life and can be tuned to detect lower glucose concentrations than current systems.

Many current biosensors use enzymes that bind glucose and produce an electric current proportional to the concentration of glucose in the blood sample. The new technique uses a chemical sensor, which is more robust and is not affected by high temperatures or changes in pH. Furthermore, it has the potential to accurately detect a wider range of glucose concentrations above and below current biosensor ranges, which may be useful in neonatal glucose sensing.

The new sensor is based on the chemical boronic acid, which is attached to a graphene foam surface. An electroactive polymer layer is added on top and binds to the boronic acid. When glucose is present, it competitively binds to the boronic acid, displacing the polymer. The sensor produces an electric current proportional to how much polymer is displaced, meaning that the concentration of glucose in the sample can be accurately measured. The researchers anticipate the sensor will expand the scope of boronic acid - based glucose sensing. Their sensor is based upon electrochemical methods rather than fluorescence, thereby enabling new boronic acid – based glucose sensing approaches.

“We’re excited by our results as this is the first time this approach has been used for glucose sensing,” said Professor Tony James, who is a Royal Society Wolfson Research Merit Award holder at the University of Bath’s Department of Chemistry and helped supervise the project. “We are still in the early stages of optimizing sensitivity and reproducibility but hope this new technology could be used in a wide range of applications, from medical sensing to food production. It could also be adapted to sense other molecules or for use in continuous flow systems.”

“Now, with this project alongside the University of Bath, we are beginning to see some of that potential being realized to create a more cost-effective and therefore accessible platform by using a new, enzyme-free glucose monitoring sensor solution,” said Dr. Marco Caffio, Co-Founder and CSO of Integrated Graphene, said: “When we started Integrated Graphene. “Now that we have proved this technique, it opens up the opportunity to take the underlying applied methodology to a vast range of similar point-of-care diagnostics that could profit from associated benefits such as reduced cost and enhanced shelf-life.”

Related Links:
University of Bath 
Integrated Graphene 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Automated Urinalysis Solution
UN-9000
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.